Plaisance Capital Management
Natick, Massachusetts, United StatesFounded 2020
Plaisance Capital Management is a venture capital firm established in 2020 that focuses on discovering, nurturing, and investing in promising biotechnology startups, particularly those committed to solving healthcare challenges. Their strategy involves a research-driven investment approach guided by scientific expertise, providing both capital and mentorship to their portfolio companies.
60% of their portfolio is in Healthcare. Deal activity increased 200% year-over-year (3 deals in the last 12 months). Their most common stage is series-a (40% of deals). Average disclosed round size is $67.8M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series A
Last 12 Mo
3
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 BlossomHill Therapeutics | Series B | $84M | Dec 2025 |
 Full-Life Technologies | Series C | $77M | Sep 2025 |
| Full-Life Technologies | Series C | $50M | Sep 2025 |
| RReunion Neuroscience Inc. | Series A | $103M | May 2024 |
 Stellaromics | Series A | $25M | Nov 2023 |
Top Co-Investors
Prosperity7 Ventures2 shared
Junson Capital2 shared
Summer Capital2 shared
Janus Henderson Investors1 shared
BioTrack Capital1 shared
Cormorant Asset Management1 shared
OrbiMed1 shared
Vivo Capital1 shared
MPM BioImpact1 shared
Novo Holdings1 shared
Arkin Bio Ventures1 shared
Palo Santo1 shared
Chengwei Capital1 shared
HSG1 shared
Last updated: 18 March 2026